期刊文献+

大剂量甲氨喋呤化疗甲酰四氢叶酸钙解救治疗骨肉瘤 被引量:7

下载PDF
导出
摘要 大剂量甲氨喋呤化疗甲酰四氢叶酸钙解救(high-dose methotrexate calcium folinate rescue,HD-MTX-CF-R)治疗骨肉瘤在临床上取得了显著疗效。其主要机制是依靠增加细胞外药物浓度提高进入细胞内药物量和促进细胞内多聚谷氨酸MTX(polyglatumated methotrexate,MTX-PG)的量增加来实现的。不同的作者分别提出MTX平均血峰浓度≥1 000μmol/L≥700μmol/L或AUC≥4 000μmol/(L.h)为达到完全反应的血药浓度指导水平。用药剂量、联合用药、年龄因素、生物钟均影响血峰浓度。临床常规的水化和尿液碱化能达到全部溶解MTX及代谢物的要求,排泄延迟的机率在大年龄组(>20岁)出现高于小年龄组,抢救排泄延迟除了用大剂量的CF解救外,使用羧肽酶-G2(carboxypeptidase-G2,CPDG2)解救是较为有效的方法之一。
出处 《肿瘤》 CAS CSCD 北大核心 2006年第9期866-869,共4页 Tumor
  • 相关文献

参考文献24

  • 1WILLIAMS W. Principles and practice of pediatric oncology [M],4th edition. Philadelphia : Lippincott, 2002:1051-1090.
  • 2CHABNER B A, YOUNG R C. Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous targe tissues[J]. Clin Invest, 1973,52(8):1804- 1811.
  • 3SYNOLD T W, RELLING M V, BOYETT J M,et al. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage,ploidy,and methotrexate dose in acute lymphoblastic leukemia[J]. Clin Invest, 1994,94(5) : 1996-2001.
  • 4DELEPINE N, DELEPINE G,JASMIN C, et al. Importance of age and methotrexate dosage: prognosis in children and young adults with high-grade osteosarcomas[J]. Biomed Pharmacother,1988,42(2) :257-262.
  • 5GRAF N, WINKLER K, BETLEMOVIC M,et al. Methotrexate pharmacokinetics and prognosis in osteosarcoma[J]. Clin Oncol, 1994,12(7) : 1443-1451.
  • 6BACCI G, FERRARI S, DELEPINE N, et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high dose methotrexate, doxorubicin, and cisplatin[J]. Clin Oncol, 1998,16(2) :658-663.
  • 7ZELCER S, KELLICK M,WEXI.ER L H,et al. Methotrexate levels and outcome in osteosarcoma[J]. Pediatr Blood Cancer,2005,44(7) :638-642.
  • 8BACCI G, LORO L, LONGHI A, et al. No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma[J]. Anticancer Drugs ,2006 , 17(4) :411-415.
  • 9IRENE A, AZUCENNA A, JOAQUIN G, et al. Methotrexate pharmacokinetics and survival in osteosarcoma[J]. Pediatr Blood Cancer, 2004,42(1): 52-58.
  • 10ESELGRIM M,GRUNERT H,KUHNE T,et al. Dose intensity of chemotherapy for anosteosarcoma d outcome in the Cooperative Osteosarcoma Study Group(COSS) trials[J]. Pediatr Blood Cancer, 2006,47(1):42-50.

同被引文献21

  • 1高科攀,王峰,蒋新国,陆国椿.大鼠血浆和脑脊液中甲氨蝶呤浓度测定及其应用[J].中国临床药学杂志,2005,14(1):23-26. 被引量:10
  • 2倪劲松,辛颖,王心蕊,石博,陈迪,田阔,吴家祥.20(S)-人参皂苷Rg_3与化疗药物联合应用对S180肉瘤的影响[J].吉林大学学报(医学版),2005,31(5):705-708. 被引量:5
  • 3Gilman G. The pharmacological basis of therapeutics[M]. 10版.金有豫,主译.北京:人民卫生出版社,2004:1089-1090.
  • 4陈新谦,金有豫,汤光.新编药物学[M].17版.北京:人民卫生出版社,2011:3465.
  • 5严汝庆 王峰 张毕奎 等.大剂量化疗时人血浆中甲氨喋呤RP-HPLC测定方法.湖南药学,2002,4(4):166-167.
  • 6Yasunofi Ariyoshi, Masashi Shimahara, Nobuhiko Tanigawa, et al. Study on cheosensitvity of oral squamous cell carcinomas by histoculture drug response assay[J]. Orol Oncology,2003,39(7) :701.
  • 7Jun Shen, Canhua Huang, Lu Jiang, et al. Enhancement of eisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell [ J ]. Biochemical Pharmacology, 2007,73 (12) : 1901.
  • 8Lixia Hou, Yonghui Shi, Pei Zhai, et al. Antibacterial activity and in vitro anti - tumor activity of the extract of the larvae of the housefly (Musca domestica ) [ J ]. Journal of Ethnopharmacology , 2007,111 (2) : 227.
  • 9Lawrence N J, Rennison D, Mcgown AT, et al. Linked parallel sythesis and MTT bioassay sceening of substituted chalcones. [ J]. Comb Chem, 2005,3 (5) :421.
  • 10DUPUIS C, MERCIER C, YANG C, et al. High-dose meth- otrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy [ J ]. Anticancer Drugs, 2008,19 ( 3 ) : 267- 273.

引证文献7

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部